High incidence of MDR and XDR Pseudomonas aeruginosa isolates obtained from patients with ventilator-associated pneumonia in Greece, Italy and Spain as part of the MagicBullet clinical trial
| UDC.coleccion | Investigación | |
| UDC.departamento | Fisioterapia, Medicina e Ciencias Biomédicas | |
| UDC.endPage | 1252 | |
| UDC.grupoInv | Investigación en Microbiología (INIBIC) | |
| UDC.institutoCentro | INIBIC - Instituto de Investigacións Biomédicas de A Coruña | |
| UDC.issue | 5 | |
| UDC.journalTitle | Journal of Antimicrobial Chemotherapy | |
| UDC.startPage | 1244 | |
| UDC.volume | 74 | |
| dc.contributor.author | Pérez Gómez, Astrid | |
| dc.contributor.author | Gato, Eva | |
| dc.contributor.author | Pérez-Llarena, Francisco J. | |
| dc.contributor.author | Fernández-Cuenca, Felipe | |
| dc.contributor.author | Gude, María José | |
| dc.contributor.author | Oviaño, Marina | |
| dc.contributor.author | Pachón, María Eugenia | |
| dc.contributor.author | Garnacho-Montero, José | |
| dc.contributor.author | González-Galán, Verónica | |
| dc.contributor.author | Pascual, Álvaro | |
| dc.contributor.author | Cisneros, José Miguel | |
| dc.contributor.author | Bou, Germán | |
| dc.date.accessioned | 2026-03-13T08:51:12Z | |
| dc.date.available | 2026-03-13T08:51:12Z | |
| dc.date.issued | 2019-02-08 | |
| dc.description.abstract | [Abstract] Objectives: To characterize the antimicrobial susceptibility, molecular epidemiology and carbapenem resistance mechanisms in Pseudomonas aeruginosa isolates recovered from respiratory tract samples from patients with ventilator-associated pneumonia enrolled in the MagicBullet clinical trial. Methods: Isolates were collected from 53 patients from 12 hospitals in Spain, Italy and Greece. Susceptibility was determined using broth microdilution and Etest. MALDI-TOF MS was used to detect carbapenemase activity and carbapenemases were identified by PCR and sequencing. Molecular epidemiology was investigated using PFGE and MLST. Results: Of the 53 isolates, 2 (3.8%) were considered pandrug resistant (PDR), 19 (35.8%) were XDR and 16 (30.2%) were MDR. Most (88.9%) of the isolates from Greece were MDR, XDR or PDR, whereas fewer of the isolates from Spain (33.3%) and Italy (43.5%) showed antibiotic resistance. Three Greek isolates were resistant to colistin. Overall, the rates of resistance of P. aeruginosa isolates to imipenem, ciprofloxacin, ceftolozane/tazobactam and ceftazidime/avibactam were 64.1%, 54.7%, 22.6% and 24.5%, respectively. All isolates resistant to ceftolozane/tazobactam and ceftazidime/avibactam (Greece, n = 10; and Italy, n = 2) carried blaVIM-2. Spanish isolates were susceptible to the new drug combinations. Forty-eight restriction patterns and 27 STs were documented. Sixty percent of isolates belonged to six STs, including the high-risk clones ST-111, ST-175 and ST-235. Conclusions: MDR/XDR isolates were highly prevalent, particularly in Greece. The most effective antibiotic against P. aeruginosa was colistin, followed by ceftolozane/tazobactam and ceftazidime/avibactam. blaVIM-2 is associated with resistance to ceftolozane/tazobactam and ceftazidime/avibactam, and related to highly resistant phenotypes. ST-111 was the most frequent and disseminated clone and the clonal diversity was lower in XDR and PDR strains. | |
| dc.description.sponsorship | This work was supported by the MagicBullet study. The European Union Directorate-General funded MagicBullet for Research and Innovation through the Seventh Framework Program for Research and Development (grant agreement 278232). Funding was also provided by the National Plan for Scientific Research, Development and Technological Innovation 2013–2016 and funded by the ISCIII-General Subdirection of Assessment and Promotion, Spanish Network for Research in Infectious Diseases (RD16/0016/0006) – co-financed by European Development Regional Fund ‘A way to achieve Europe'. This work was supported by the Fondo de Investigación Sanitaria (grant PI15/00860 to G. B.), integrated in the Plan Nacional de I+D and funded by the Instituto de Salud Carlos III (ISCIII). A. P. was supported by grant IJCI-2016-29524. | |
| dc.identifier.citation | Pérez A, Gato E, Pérez-Llarena J, Fernández-Cuenca F, Gude MJ, Oviaño M, Pachón ME, Garnacho J, González V, Pascual Á, Cisneros JM, Bou G. High incidence of MDR and XDR Pseudomonas aeruginosa isolates obtained from patients with ventilator-associated pneumonia in Greece, Italy and Spain as part of the MagicBullet clinical trial. J Antimicrob Chemother. 2019 May 1;74(5):1244-1252. | |
| dc.identifier.doi | 10.1093/JAC/DKZ030 | |
| dc.identifier.issn | 1460-2091 | |
| dc.identifier.uri | https://hdl.handle.net/2183/47725 | |
| dc.language.iso | eng | |
| dc.publisher | Oxford University Press | |
| dc.relation.projectID | info:eu-repo/grantAgreement/EC/FP7/278232/EU | |
| dc.relation.projectID | info:eu-repo/grantAgreement/MINECO//RD16%2F0016%2F0006/ES/RED ESPAÑOLA DE INVESTIGACIÓN EN PATOLOGÍAS INFECCIOSAS/ | |
| dc.relation.uri | https://doi.org/10.1093/JAC/DKZ030 | |
| dc.rights | This is a pre-copyedited, author-produced version of an article accepted for publication in Journal of Antimicrobial Chemotherapy following peer review. The version of record [insert complete citation information here] is available online at Oxford Academic web page. | |
| dc.rights.accessRights | open access | |
| dc.subject | Drug Resistance, Multiple, Bacterial | |
| dc.subject | Pneumonia, Ventilator-Associated | |
| dc.subject | Pseudomonas Infections | |
| dc.subject | Pseudomonas aeruginosa | |
| dc.title | High incidence of MDR and XDR Pseudomonas aeruginosa isolates obtained from patients with ventilator-associated pneumonia in Greece, Italy and Spain as part of the MagicBullet clinical trial | |
| dc.type | journal article | |
| dc.type.hasVersion | AM | |
| dspace.entity.type | Publication | |
| relation.isAuthorOfPublication | 909e08d1-6ed1-4b99-9e9e-c64eb72e7dea | |
| relation.isAuthorOfPublication.latestForDiscovery | 909e08d1-6ed1-4b99-9e9e-c64eb72e7dea |
Files
Original bundle
1 - 1 of 1

